Classical as well as novel antipsychotic drugs increase self-stimulation threshold in the rat - Similar mechanism of action?

European Journal of Pharmacology

Volumn 544, Issue 1-3, 2006, Pages 69-76

  Flagstad, Peter ^a   Arnt, Jørn ^a   Olsen, Christina K ^a  

^a H LUNDBECK A S   (Denmark)

Author keywords

Antipsychotic; In vivo; Intracranial self stimulation; Reward; Specific receptor antagonists

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; CLOZAPINE; DOPAMINE 2 RECEPTOR; HALOPERIDOL; MUSCARINIC RECEPTOR; NEUROLEPTIC AGENT; OLANZAPINE; SEROTONIN 2A RECEPTOR; SERTINDOLE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SELF STIMULATION;

ANIMALS; ANTIPSYCHOTIC AGENTS; BEHAVIOR, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HALOPERIDOL; MALE; MOTIVATION; RATS; RATS, WISTAR; RECEPTORS, ADRENERGIC, ALPHA-1; RECEPTORS, DOPAMINE D2; RECEPTORS, SEROTONIN; SELF STIMULATION;

EID: 33746621995     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2006.06.051     Document Type: Article

References (40)

1. Arnt J. Differential effects of classical and newer antipsychotics on the hypermotility induced by two dose levels of D-amphetamine. Eur. J. Pharmacol. 283 (1995) 55-62
2. Arnt J. Inhibitory effects on the discriminative stimulus properties of D-amphetamine by classical and newer antipsychotics do not correlate with antipsychotic activity. Relation to effects on the reward system?. Psychopharmacology 124 (1996) 117-125
3. Arnt J., and Skarsfeldt T. Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology 18 (1998) 63-101
4. 1 agonist elevates self-stimulation thresholds: comparison to other dopamine-selective drugs. Pharmacol. Biochem. Behav. 62 (1999) 659-672
5. Benaliouad F., Kapur S., and Rompre P. Blockade of 5-HT2A receptors reduces the attenuation of brain stimulation reward by haloperidol. Soc. Neurosci. Abstr. (2005)
6. Buis W. Patients' opinions concerning side effects of depot neuroleptics. Am. J. Psychiatry 149 (1992) 844-845
7. Campbell K.A., Evans G., and Gallistel C.R. A microcomputer-based method for physiologically interpretable measurement of the rewarding efficacy of brain stimulation. Physiol. Behav. 35 (1985) 395-403
8. Deutch A.Y., Moghaddam B., Innis R.B., Krystal J.H., Aghajanian G.K., Bunney B.S., and Charney D.S. Mechanisms of action of atypical antipsychotic drugs. Implications for novel therapeutic strategies for schizophrenia. Schizophr. Res. 4 (1991) 121-156
9. Druhan J.P., Fibiger H.C., and Phillips A.G. Differential effects of cholinergic drugs on discriminative cues and self-stimulation produced by electrical stimulation of the ventral tegmental area. Psychopharmacology 97 (1989) 331-338
10. Fibiger H.C., LePiane F.G., Jakubovic A., and Phillips A.G. The role of dopamine in intracranial self-stimulation of the ventral tegmental area. J. Neurosci. 7 (1987) 3888-3896
11. Frank R.A., Tsibulsky V., Grocki S., Dashevsky B., Kehne J.H., Schmidt C.J., and Sorensen S.M. Mixed D2/5-HT2A antagonism of amphetamine-induced facilitation of brain stimulation reward. Pharmacol. Biochem. Behav. 52 (1995) 799-804
12. Gallistel C.R., and Davis A.J. Affinity for the dopamine D2 receptor predicts neuroleptic potency in blocking the reinforcing effect of MFB stimulation. Pharmacol. Biochem. Behav. 19 (1983) 867-872
13. Greenshaw A.J.A. Differential effects of ondansetron, haloperidol and clozapine on electrical self-stimulation of the ventral tegmental area. Behav. Pharmacol. 4 (1993) 479-485
14. Harrow M., Yonan C.A., Sands J.R., and Marengo J. Depression in schizophrenia: are neuroleptics, akinesia, or anhedonia involved?. Schizophr. Bull. 20 (1994) 327-338
15. Hunt G.E., and Atrens D.M. Parametric manipulations and fixed-interval self-stimulation. Physiol. Behav. 51 (1992) 1009-1020
16. Ivanova S., and Greenshaw A.J. Nicotine-induced decreases in VTA electrical self-stimulation thresholds: blockade by haloperidol and mecamylamine but not scopolamine or ondansetron. Psychopharmacology 134 (1997) 187-192
17. Kapur S., VanderSpek S.C., Brownlee B.A., and Nobrega J.N. Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy. J. Pharmacol. Exp. Ther. 305 (2003) 625-631
18. Kinon B.J., and Lieberman J.A. Mechanisms of action of atypical antipsychotic drugs: a critical analysis. Psychopharmacology 124 (1996) 2-34
19. Kling-Petersen T., and Svensson K. A simple computer-based method for performing and analyzing intracranial self-stimulation experiments in rats. J. Neurosci. Methods 47 (1993) 215-225
20. Lader M.H. Neuroleptic-induced deficit syndrome (NIDS). J. Clin. Psychiatry 54 (1993) 493-500
21. Lewander T. Neuroleptics and the neuroleptic-induced deficit syndrome. Acta Psychiatr. Scand. 89 (1994) 8-13
22. Lindström L. Long-term clinical and social outcome studies in schizophrenia in relation to the cognitive and emotional side effects of antipsychotic drugs. Acta Psychiatr. Scand. 89 suppl 380 (1994) 74-76
23. Markou A., and Koob G.F. Intracranial self-stimulation thresholds as a measure of reward. In: Sahgal A. (Ed). Behavioural Neuroscience: A Practical Approach (1993), IRL Press, Oxford 93-115
24. Miliaressis E., Rompre P.P., Laviolette P., Philippe L., and Coulombe D. The curve-shift paradigm in self-stimulation. Physiol. Behav. 37 (1986) 85-91
25. Moser P.C., Moran P.M., Frank R.A., and Kehne J.H. Reversal of amphetamine-induced behaviours by MDL 100,907, a selective 5-HT2A antagonist. Behav. Brain Res. 73 (1996) 163-167
26. Naber D. A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables. Int. Clin. Psychopharmacol. 10 (1995) 133-138
27. Nakajima S., and Patterson R.L. The involvement of dopamine D2 receptors, but not D3 or D4 receptors, in the rewarding effect of brain stimulation in the rat. Brain Res. 760 (1997) 74-79
28. Nielsen C.K., Arnt J., and Sánchez C. Intracranial self-stimulation and sucrose intake differ as hedonic measures following chronic mild stress: interstrain and interindividual differences. Behav. Brain Res. 107 (2000) 21-33
29. Paxinos G., and Watson C. The Rat Brain in Stereotaxic Coordinates. Fourth Edition (1998), Academic Press, San Diego
30. Phillips A.G. Brain reward circuitry: a case for separate systems. Brain Res. Bull. 12 (1984) 195-201
31. Sanchez C., and Arnt J. In-vivo assessment of 5-HT2A and 5-HT2C antagonistic properties of newer antipsychotics. Behav. Pharmacol. 11 (2000) 291-298
32. Sanchez C., Arnt J., Dragsted N., Hyttel J., Lembøl H.L., Meier E., Perregaard J., and Skarsfeldt T. Neurochemical and in vivo pharmacological profile of sertindole, a limbic-selective neuroleptic compound. Drug Dev. Res. 22 (1991) 239-250
33. Schaefer G.J., and Michael R.P. Acute effects of neuroleptics on brain self-stimulation thresholds in rats. Psychopharmacology 67 (1980) 9-15
34. Szewczak M.R., Corbett R., Rush D.K., Wilmot C.A., Conway P.G., Strupczewski J.T., and Cornfeldt M. The pharmacological profile of iloperidone, a novel atypical antipsychotic agent. J. Pharmacol. Exp. Ther. 274 (1995) 1404-1413
35. 2 modulation of psychostimulant-induced facilitation of brain stimulation reward. Drug Dev. Res. 34 (1995) 297-305
36. Tsibulsky V.L., Grocki S., Dashevsky B.A., Kehne J.H., Schmidt C.J., Sorensen S.M., and Frank R.A. Mixed D2/5-HT2A antagonism of cocaine-induced facilitation of brain stimulation reward. Pharmacol. Biochem. Behav. 59 (1998) 275-280
37. Van-Putten T., May P.R., Marder S.R., and Wittmann L.A. Subjective response to antipsychotic drugs. Arch. Gen. Psychiatry 38 (1981) 187-190
38. Voruganti L., Cortese L., Oyewumi L., Cernovsky Z., Zirul S., and Awad A. Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life. Schizophr. Res. 43 (2000) 135-145
39. Wise R.A. Catecholamine theories of reward: a critical review. Brain Res. 152 (1978) 215-247
40. Wise R.A. Neuroleptics and operant behavior: the anhedonia hypothesis. Behav. Brain Sci. 5 (1982) 39-87